HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

JPM 565

structure in first source

Also Known As:

JPM-565; JPM-OEt

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - Branched-Chain Amino Acids: 2289
    - Leucine: 6718
      - JPM 565: 3
  - Essential Amino Acids: 1152
    - Leucine: 6718
      - JPM 565: 3

Experts

1.	Bogyo, Matthew: 2 articles (08/2008 - 08/2007)
2.	Anbalagan, Arulselvi: 1 article (03/2012)
3.	Anderson, Robin L: 1 article (03/2012)
4.	Bidwell, Bradley N: 1 article (03/2012)
5.	Blum, Galia: 1 article (03/2012)
6.	Bogyo, Matthew S: 1 article (03/2012)
7.	Edgington, Laura: 1 article (03/2012)
8.	Moin, Kamiar: 1 article (03/2012)
9.	Olive, Mary B: 1 article (03/2012)
10.	Parker, Belinda S: 1 article (03/2012)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2008 - "The invasive strand formation of collagen I-embedded tumour cell spheroids generated from primary tumours of inhibitor-treated mice in the early cancer trial could be inhibited in vitro by JPM-OEt; a result arguing against induction of resistance to the inhibitor. " 08/01/2008 - "Here, we report the treatment of polyoma middle T oncogene-induced breast cancers in mice with the cell-permeable broad-spectrum cysteine cathepsin inhibitor JPM-OEt. " 08/01/2007 - "Inhibition of the cysteine cathepsin family using a pan-cathepsin inhibitor, JPM-OEt, led to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis. " 03/01/2012 - "Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. "
2.	Breast Neoplasms (Breast Cancer) 08/01/2008 - "We conclude that the pharmacokinetic properties of JPM-OEt, which result in poor bioavailability, may prohibit its use for stand-alone treatment of solid mammary cancers and their lung metastases." 08/01/2008 - "Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model." 08/01/2008 - "Measurement of cysteine cathepsin activities in tissue extracts after intraperitoneal injection of JPM-OEt revealed effective inhibition of cysteine cathepsins in pancreas, kidneys and liver, while activities in mammary cancers and in lungs were not significantly affected. "
3.	Neoplasm Metastasis (Metastasis) 08/01/2008 - "We conclude that the pharmacokinetic properties of JPM-OEt, which result in poor bioavailability, may prohibit its use for stand-alone treatment of solid mammary cancers and their lung metastases." 03/01/2012 - "Similarly, intraperitoneal administration of the highly selective cathepsin B inhibitor CA-074 reduced metastasis in tumor-bearing animals, a reduction that was not reproduced by the broad spectrum cysteine cathepsin inhibitor JPM-OEt. "
4.	Carcinogenesis 08/01/2007 - "Inhibition of the cysteine cathepsin family using a pan-cathepsin inhibitor, JPM-OEt, led to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis. "

Related Drugs and Biologics

1.	Cysteine (L-Cysteine)
2.	Cathepsins
3.	Collagen
4.	Tissue Extracts
5.	Cathepsin B
6.	N- (3- propylcarbamoyloxirane- 2- carbonyl)- isoleucyl- proline

Related Therapies and Procedures

1.	Intraperitoneal Injections